According to this year’s Parkinson’s Foundation State of the Community Survey, disease symptoms and medication knowledge are top concerns for the Parkinson’s disease community. More than half of the participants identified motor symptoms (61%), especially tremor, gait, and balance issues, and nonmotor symptoms (52%), including sleep,…
News
Scenic Biotech has joined the LRRK2 Investigative Therapeutics Exchange (LITE) program to study its PLA2G15 inhibitors as a potential treatment approach for Parkinson’s disease, including in people with LRRK2 gene mutations. The program is an initiative from The Michael J. Fox Foundation (MJFF) designed to identify biomarkers…
UZ Leuven and KU Leuven, two institutions in Belgium, have introduced NeuroEXPLORER PET into clinical practice. The ultra-high-resolution PET scanner, developed by United Imaging Healthcare, is designed to visualize small, deep brain regions, including those involved in Parkinson’s disease. Within the first…
Neuropacs’ Automated Imaging Differentiation of Parkinsonism (AIDP) software accurately detected brain changes related to Parkinson’s disease across different patient groups, including some who tested negative on standard alpha-synuclein biomarker tests, a new study has found. The software uses a specialized MRI technique called free-water imaging. These new…
AC Immune has been awarded $4 million to extend the first part of an ongoing clinical trial that’s testing ACI-7104, its experimental vaccine targeting alpha-synuclein protein clumping, which is a hallmark of Parkinson’s disease. The grant, funded by the Vijay and Marie Goradia Charitable Foundation, will allow…
BIA 28-6156, a small-molecule therapy developed by Bial for GBA-related Parkinson’s disease, did not slow disease progression in a Phase 2 clinical trial involving people with mutations in the GBA1 gene, and the company decided to discontinue its development for the condition. Bial said that while the study…
A comprehensive review of the scientific literature identified more than 100 distinct ways in which off episodes affect people with Parkinson’s disease, highlighting a multifaceted burden that extends beyond movement symptoms to include cognitive, emotional, and quality-of-life impacts. The research was presented by Merz Therapeutics, the company that…
Foresee Pharmaceuticals’ oral therapy mirivadelgat has been selected to enter the Phase 2a SLEIPNIR platform trial, which is testing several experimental treatments for Parkinson’s disease. The trial, funded by Cure Parkinson’s and conducted in collaboration with Haukeland University Hospital in Bergen, Norway, is evaluating multiple therapeutic candidates…
Fecal microbiota transplantation (FMT), a technique for replacing gut bacteria, may help with gastrointestinal symptoms of Parkinson’s disease, particularly constipation, according to a review study. While the technique was found to be generally safe and beneficial for gastrointestinal symptoms in Parkinson’s disease, “at this stage, there is no convincing…
People with Parkinson’s disease who switched to the approved oral therapy Crexont, an extended-release formulation of carbidopa and levodopa, from other levodopa-based treatments gained about three additional hours of daily good on time — when symptoms are well-controlled — while also experiencing less off time, or periods…
Recent Posts
- Combined cognitive, biomarker testing targets Parkinson’s, related disorders
- 5 ways to make your home more Parkinson’s friendly and safe
- Brain chemical changes may be tied to Parkinson’s cognitive issues
- Pivotal trial of adaptive deep brain stimulation device hits key milestone
- Parkinson’s changed my uncle’s role, but not what he brought to the table